SABS

SAB Biotherapeutics, Inc.

3.96 USD
+0.16 (+4.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

SAB Biotherapeutics, Inc. stock is down -11.21% since 30 days ago. The next earnings date is May 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 May’s closed higher than April.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.